AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Archives: News
Catana Capital: New collaboration with Life Science AI pioneer Innoplexus
Catana Capital partners with a leading provider of AI solutions in the Life Science sector Frankfurt am Main, December 16, 2019: As a pioneer in the application of Big Data and AI for quantitative asset management, Catana Capital is always open to collaborate with other innovators in the space in order to develop new innovative investment …
Catana Capital: New collaboration with Life Science AI pioneer Innoplexus Read More »
Innoplexus and Wiley partner to provide AI-powered solutions over comprehensive research literature
Frankfurt, Germany, October 15, 2019 – Innoplexus AG announces a partnership with John Wiley & Sons, Inc. (NYSE: JW-A) (NYSE: JW-B) to enable Innoplexus’s proprietary, ontology-driven search and artificial intelligence-powered analysis on the full text of life science articles published by Wiley, one of the largest scientific and scholarly publishing houses in the world. This …
Innoplexus and ChemAxon partner to get more out of life science data
Frankfurt, Germany – Budapest, Hungary, September 16, 2019 – Innoplexus announces an official partnership with ChemAxon, getting the most value out from life sciences data. Through the joint venture, Innoplexus will enable big pharma and biotech companies to find and connect information about pharmaceutical compounds from publicly available, or archived enterprise datasets to generate novel …
Innoplexus and ChemAxon partner to get more out of life science data Read More »
Innoplexus Announces Appointment of Stratos Davlos as Chief Technology Officer (CTO) and Senior Vice President
Hoboken, New Jersey, September 16, 2019- Innoplexus Inc., a subsidiary of Innoplexus AG, announced today the appointment of Stratos Davlos as Chief Technology Officer (CTO) and Senior Vice President. Mr. Davlos is a highly accomplished artificial intelligence and machine learning executive with over 20 years of leadership experience. Prior to joining Innoplexus, Mr. Davlos was …
Traum aller Anleger
Innoplexus aus Eschborn und der Vermögensverwalter Acatis aus Frankfurt testen eine neue KI-Maschine für die Geldanlage. Der 21. März 2019 bleibt den Aktionären des Pharmakonzerns Biogen in schmerzhafter Erinnerung. Kurz vor Börsenbeginn hatte der in Cambridge, Massachusetts, aufgehende Stern am Biotech-Himmel die Investoren darüber unterrichtet, dass er eine klinische Studie mit seinem Alzheimer-Präparat „Aducanumab“ abbrechen …
Innoplexus Announces Appointment of Rita Kelley as Senior Vice President and Managing Director, USA
Hoboken, New Jersey, September 12, 2019 – Innoplexus Inc, a subsidiary of Innoplexus AG, Frankfurt, which has developed the most comprehensive, industry validated, AI-powered Drug Discovery and Development platform, announced today the appointment of Rita Kelley as Senior Vice President Corporate Development and Marketing. Rita will also act as Managing Director USA. Ms. Kelley is …
Innoplexus and Cures Within Reach for Cancer Tap the Power of Artificial Intelligence to Find Off-Patent Non-Cancer Drugs That Have Potential to Treat Cancer
Hoboken, NJ, August 5, 2019 – Innoplexus Holdings, Inc., a leader in artificial intelligence (AI) solutions for the life sciences industry, has partnered with the nonprofit Cures Within Reach for Cancer to pave the way for faster and more effective identification of new, affordable cancer treatments among existing non-cancer generic and off-patent drugs. Innoplexus is …
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific AI prediction engine, which recently caught attention by correctly predicting that Biogen’s Alzheimer’s drug aducanumab would fail with 70% to 90% certainty. Allie Nawrat finds out more. In March 2019, Biogen’s long anticipated drug for …
AI CTP engine estimated failure for Biogen’s aducanumab Read More »
Predicting Drug Flops with AI
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific AI prediction engine, which recently caught attention by correctly predicting that Biogen’s Alzheimer’s drug aducanumab would fail with 70% to 90% certainty. Allie Nawrat finds out more. n March 2019, Biogen’s long anticipated drug for …